secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-022894
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences Q3 revenue $7.4M, net loss $23.9M; discontinues PBCAR269A program
--------------------------------------------------------------------------------

- Net loss of $23.9M ($0.22 loss per share) vs $11.3M loss ($0.19) in Q3 2021.
- Revenue $7.4M, down 69% from $24M YoY; decrease primarily from absence of iECURE revenue.
- Cash $212.1M; expects runway to fund operations through end of 2024.
- Discontinued BCMA CAR T program PBCAR269A due to competitive landscape; no further clinical spending planned.
- Planned clinical update for azer-cel (PBCAR0191) and PBCAR19B in late Q4 2022 or early Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017022022894/0000950170-22-022894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017022022894/dtil-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer